Sprint Bioscience AB (publ) (STO:SPRINT)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.885
-0.010 (-0.53%)
At close: Mar 6, 2026
34.84%
Market Cap 198.90M
Revenue (ttm) 167.17M
Net Income (ttm) 91.74M
Shares Out 105.52M
EPS (ttm) 0.98
PE Ratio 1.92
Forward PE 6.28
Dividend n/a
Ex-Dividend Date n/a
Volume 378,030
Average Volume 1,240,179
Open 1.900
Previous Close 1.895
Day's Range 1.815 - 1.910
52-Week Range 0.360 - 2.350
Beta -0.62
RSI 48.51
Earnings Date Feb 12, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 30
Stock Exchange Nasdaq Stockholm
Ticker Symbol SPRINT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.